Last reviewed · How we verify
Degarelix acetate, Leuprolide acetate — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Degarelix acetate, Leuprolide acetate (Degarelix acetate, Leuprolide acetate) — Urology of Virginia.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Degarelix acetate, Leuprolide acetate TARGET | Degarelix acetate, Leuprolide acetate | Urology of Virginia | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Degarelix acetate, Leuprolide acetate CI watch — RSS
- Degarelix acetate, Leuprolide acetate CI watch — Atom
- Degarelix acetate, Leuprolide acetate CI watch — JSON
- Degarelix acetate, Leuprolide acetate alone — RSS
Cite this brief
Drug Landscape (2026). Degarelix acetate, Leuprolide acetate — Competitive Intelligence Brief. https://druglandscape.com/ci/degarelix-acetate-leuprolide-acetate. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab